ストックスクリーナーアプリを入手
2.22
4.72%
-0.11
アフターアワーズ：
2.20
-0.02
-0.90%
前日終値:
$2.33
開ける：
$2.33
24時間の取引高:
2.66M
Relative Volume:
1.67
時価総額：
$240.63M
収益：
$42.51M
当期純損益:
$-116.49M
株価収益率:
-1.9821
EPS:
-1.12
ネットキャッシュフロー:
$-120.82M
1週間 パフォーマンス:
+20.65%
1か月 パフォーマンス:
+63.24%
6か月 パフォーマンス:
-43.65%
1年 パフォーマンス:
-66.67%
1日の値動き範囲:
$2.125
$2.37
1週間の範囲:
$1.905
$2.6691
52週間の値動き範囲:
$1.03
$12.02
Tango Therapeutics Inc Stock (TNGX) Company Profile
TNGX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
2.22 | 199.45M | 42.51M | -116.49M | -120.82M | -1.12 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-07-17 | 開始されました | Jefferies | Buy |
| 2024-04-04 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-02-12 | 開始されました | Piper Sandler | Overweight |
| 2023-12-08 | 開始されました | B. Riley Securities | Buy |
| 2022-10-20 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Tango Therapeutics Inc (TNGX) 最新ニュース
Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference - GlobeNewswire
Tango Therapeutics CEO Barbara Weber to Share Exclusive Insights at Major Goldman Sachs Healthcare Conference - Stock Titan
D. E. Shaw & Co. Inc. Takes $355,000 Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Acquired by Northern Trust Corp - Defense World
Tango Therapeutics doses first subject in trial for MTAP-deleted tumours - Yahoo Finance
Tango Therapeutics starts trial for brain cancer drug By Investing.com - Investing.com South Africa
Tango Therapeutics starts trial for brain cancer drug - Investing.com Australia
Tango Therapeutics, Inc. Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients with MTAP-Deleted Glioblastoma and Other Solid Tumors - marketscreener.com
Tango Therapeutics Doses First Patient for Phase 1/2 Trial to Treat Brain Cancer - marketscreener.com
TNGX Initiates Phase 1/2 Trial for MTAP-Deleted Tumors | TNGX Stock News - GuruFocus
Tango Therapeutics Announces First Patient Dosed in TNG456 - GlobeNewswire
Tango Launches Phase 1/2 Trial for Brain Cancer Drug: New Hope for Deadly Glioblastoma Treatment - Stock Titan
Cantor Fitzgerald Issues Positive Estimate for TNGX Earnings - Defense World
Leerink Partnrs Analysts Boost Earnings Estimates for TNGX - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Just Reported Earnings, And Analysts Cut Their Target Price - Yahoo Finance
US$10.43: That's What Analysts Think Tango Therapeutics, Inc. (NASDAQ:TNGX) Is Worth After Its Latest Results - simplywall.st
Dimensional Fund Advisors LP Purchases 302,087 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue Estimates - MSN
Tango Therapeutics First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Tango Therapeutics, Inc. (NASDAQ:TNGX) Holdings Boosted by Wells Fargo & Company MN - Defense World
Tango Therapeutics Extends Cash Runway Amid Clinical Progress - TipRanks
Tango Therapeutics (TNGX) Plans $400 Million Mixed Securities Sh - GuruFocus
Tango Therapeutics Files For Mixed Shelf Of Up To $400 Million - marketscreener.com
Tango Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Tango Therapeutics Inc (TNGX) Q1 2025 Earnings: EPS of -$0.36 Mi - GuruFocus
TNGX Reports Q1 Revenue Miss, Advances Cancer Treatments | TNGX Stock News - GuruFocus
Tango Therapeutics Inc (TNGX) Q1 2025 Earnings: EPS of -$0.36 Misses Estimate, Revenue Falls Short at $5.4 Million - GuruFocus
Tango Therapeutics, Inc. SEC 10-Q Report - TradingView
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights - GlobeNewswire
Barclays PLC Has $307,000 Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics (TNGX) to Release Earnings on Monday - Defense World
Insights into Tango Therapeutics's Upcoming Earnings - Nasdaq
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of “Buy” by Analysts - Defense World
21,500 Shares in Tango Therapeutics, Inc. (NASDAQ:TNGX) Acquired by Renaissance Technologies LLC - Defense World
JPMorgan Chase & Co. Has $97,000 Stock Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Medivir's Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study - Barchart.com
There is no way Tango Therapeutics Inc (TNGX) can keep these numbers up - Sete News
Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - GlobeNewswire
Is Tango Therapeutics Inc (TNGX) worth investing in despite its undervalued state? - uspostnews.com
Tango Therapeutics Inc (TNGX) Stock: A Year of Highs and Lows - investchronicle.com
Insider’s View: Deciphering Tango Therapeutics Inc (TNGX)’s Financial Health Through Ratios - DWinneX
Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace
Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Acquired by Geode Capital Management LLC - Defense World
Now Is The Time To Build A Position In Tango Therapeutics Inc (NASDAQ:TNGX) - Marketing Sentinel
Press Release Distribution & PR Platform - ACCESS Newswire
Gaining Ground: Tango Therapeutics Inc (TNGX) Closes Lower at 2.35, Down -0.42 - DWinneX
What is the investor’s view on Tango Therapeutics Inc (TNGX)? - uspostnews.com
Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Acquired by Franklin Resources Inc. - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives $12.33 Average PT from Analysts - Defense World
Equities Analysts Offer Predictions for TNGX Q1 Earnings - Defense World
Tango Therapeutics Inc (TNGX) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
3.74%
大文字化:
|
ボリューム (24 時間):